<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03317392</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2017-01920</org_study_id>
    <secondary_id>NCI-2017-01920</secondary_id>
    <secondary_id>10096</secondary_id>
    <secondary_id>10096</secondary_id>
    <secondary_id>UM1CA186689</secondary_id>
    <secondary_id>UM1CA186709</secondary_id>
    <nct_id>NCT03317392</nct_id>
  </id_info>
  <brief_title>Olaparib and Radium Ra 223 Dichloride in Treating Men With Metastatic Castration-Resistant Prostate Cancer That Has Spread to the Bone</brief_title>
  <official_title>A Phase 1/2 Study of Olaparib in Combination With Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the best dose and side effects of olaparib and how well it
      works with radium Ra 223 dichloride in treating patients with castration-resistant prostate
      cancer that has spread to the bone and other places in the body. Olaparib may stop the growth
      of tumor cells by blocking some of the enzymes needed for cell growth. Radioactive drugs,
      such as radium Ra 223 dichloride, may carry radiation directly to tumor cells and not harm
      normal cells. Giving olaparib and radium Ra 223 dichloride may work better at treating
      castration-resistant prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the maximum tolerated dose (MTD) of olaparib in combination with radium Ra 223
      dichloride (radium-223). (Phase 1) II. Evaluate the radiographic progression-free survival
      (rPFS). (Phase 2)

      SECONDARY OBJECTIVES:

      I. Evaluate safety and tolerability as assessed by Common Terminology Criteria for Adverse
      Events (CTCAE) version 4.0.

      II. To evaluate radiographic PFS as stratified by disease extent (=&lt; 20 or &gt; 20 bone lesions)
      and prior docetaxel use (yes or no).

      III. Evaluate radiographic PFS in patients harboring or lacking evidence of homologous
      recombination deficiency (HRD).

      IV. Evaluate prostate specific antigen (PSA) response rate as defined by &gt;= 50% decline in
      PSA from baseline.

      V. Evaluate total alkaline phosphatase response defined as a reduction of &gt;= 30% from the
      baseline value, confirmed &gt;= 4 weeks later.

      VI. Evaluate time to PSA progression as defined by Prostate Cancer Clinical Trials Working
      Group (PCTWG) 3 criteria.

      VII. Evaluate radiographic objective response rate as defined by Response Evaluation Criteria
      in Solid Tumor (RECIST) version 1.1.

      VIII. Evaluate time to increase in the total alkaline phosphatase (ALP) level defined as an
      increase of &gt;= 25% from baseline at &gt;= 12 weeks, in patients with no decrease from baseline,
      or as an increase of &gt;= 25% above the nadir, confirmed &gt;= 3 weeks later, in patients with an
      initial decrease from baseline.

      IX. Evaluate time to initiation of next active anti-cancer therapy (including androgen
      receptor[AR] signaling agents, cytotoxic chemotherapy, immunotherapy, or investigational
      agents).

      X. Evaluate time to first symptomatic skeletal event (SSE). XI. Evaluate overall survival
      (OS).

      TERTIARY OBJECTIVES:

      I. Evaluate impact on quality of life (QOL) as determined by Functional Assessment of Cancer
      Therapy-Prostate (FACT-P) questionnaire and Brief Pain Inventory (BPI).

      II. Estimate the frequency of mutations in the deoxyribonucleic acid (DNA) repair pathway in
      patients with metastatic castration-resistant prostate cancer (CRPC) as determine by
      Oncopanel testing and by whole exome sequencing (WES).

      III. Characterize changes in ribonucleic acid (RNA) expression of DNA repair genes and immune
      markers by whole transcriptome sequencing (WTS) in each arm.

      IV. Characterize changes in the peripheral T-cell and T-cell receptor repertoire at baseline,
      during treatment, and at progression in each arm.

      V. Evaluate changes in lactate dehydrogenase (LDH) in patients each treatment arm.

      VI. Assess the prevalence of germline mutations in homologous recombination genes in all
      enrolled patients.

      VII. Correlate homologous recombination gene germline mutation status with PSA response by
      treatment arm.

      VIII. Evaluate family history of cancers in the study population and correlate family cancer
      history with germline mutation status.

      OUTLINE: This is a phase I, dose-escalation study of olaparib followed by a phase II study.

      PHASE I: Patients receive radium Ra 223 dichloride intravenously (IV) over 1 minute on day 1.
      Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or
      unacceptable toxicity. Patients also receive olaparib orally (PO) twice daily (BID) on days
      1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable
      toxicity.

      PHASE II: Patients are randomized to 1 of 2 arms.

      ARM I: Patients receive radium Ra 223 dichloride IV over 1 minute on day 1. Treatment repeats
      every 28 days for up to 6 courses in the absence of disease progression or unacceptable
      toxicity. Patients also continue to receive olaparib as in Phase I.

      ARM II: Patients receive radium Ra 223 dichloride as in Arm I.

      After completion of study treatment, patients are followed up every 6 months for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 5, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of olaparib and radium Ra 223 dichloride</measure>
    <time_frame>Up to 2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiographic progression-free survival (rPFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be estimated using the Kaplan-Meier method by treatment arm. A stratified Cox proportional hazards regression model will estimate the rPFS treatment hazard ratio with 80% 2-sided confidence intervals (CIs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Radiographic progression free survival (rPFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Treatment comparison in rPFS will be conducted in pre-defined subgroups, including homologous recombination deficiency status (yes/no), disease extent (=&lt; 20 or &gt; 20 bone lesions) and prior docetaxel (yes or no). Cox regression hazard ratios (for treatment comparison) along two-sided 80% CI will be provided for each subgroup.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate specific antigen (PSA) response defined by 50% decline in PSA from baseline assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Response rate by different criteria will be summarized as number and percentage of participants by treatment arm with two-sided 80% CI and compared between groups using Fisher's exact tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkaline phosphatase (ALP) response defined as &gt;= 30% reduction of the blood level, compared to the baseline value assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Response rate by different criteria will be summarized as number and percentage of participants by treatment arm with two-sided 80% CI and compared between groups using Fisher's exact tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Response rate by different criteria will be summarized as number and percentage of participants by treatment arm with two-sided 80% CI and compared between groups using Fisher's exact tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate specific antigen (PSA) progression</measure>
    <time_frame>From randomization to PSA progression by Prostate Cancer Working Group (PCWG) 3 criteria, assessed up to 2 years</time_frame>
    <description>Will be estimated using the method of Kaplan-Meier and compared between treatment arms using the stratified log-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ALP progression</measure>
    <time_frame>From randomization to the date of first ALP progression, assessed up to 2 years</time_frame>
    <description>Will be estimated using the method of Kaplan-Meier and compared between treatment arms using the stratified log-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic skeletal event (SSE)</measure>
    <time_frame>From randomization to occurrence of the first SSE, such as pathologic bone fracture, spinal cord compression, hypercalcemia of malignancy or radiation therapy or surgery to bone, described by the US Food and Drug Administration, assessed up to 2 years</time_frame>
    <description>Will be estimated using the method of Kaplan-Meier and compared between treatment arms using the stratified log-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From randomization to the date of death due to any cause, assessed up to 2 years</time_frame>
    <description>Will be estimated using the method of Kaplan-Meier and compared between treatment arms using the stratified log-rank test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Adverse events will be summarized according to grade, overall and by treatment arm, as number and percentage of participants. All adverse events resulting in discontinuation, dose modification, and/or dosing interruption, and/or treatment delay of drug will also be summarized by treatment arm.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in levels of serum lactate dehydrogenase (LDH)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be summarized at baseline and each cycle with descriptive statistics. Percent change from baseline or status change (e.g. from normal to abnormal defined by institution upper limit level) will be reported and compared between treatment arms at selected timepoints using Wilcoxon rank sum test or Fisher's exact test as appropriate.</description>
  </other_outcome>
  <other_outcome>
    <measure>Frequency of mutations in the deoxyribonucleic acid (DNA) repair pathway</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be determined by Oncopanel testing. Gene mutation frequencies and mean +/- standard deviation of quantitative biomarkers will be summarized by arm and in overall population at baseline and/or at time of progression.</description>
  </other_outcome>
  <other_outcome>
    <measure>Homologous recombination deficiency (HRD)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Cox regression or logistic regression will be conducted to explore the association of rPFS or treatment response (PSA or tumor response) with HRD gene mutation status.</description>
  </other_outcome>
  <other_outcome>
    <measure>Prevalence of germline mutations in homologous recombination genes</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Their correlation with family history of cancers and PSA response will be evaluated using Fisher's exact test or logistic regression as appropriate in all patients and/or by treatment arm as exploratory analyses.</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life (QOL) measured using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire and Brief Pain Inventory (BPI)</measure>
    <time_frame>Baseline up to 2 years</time_frame>
    <description>For each treatment group, calculated QOL scores will be summarized at baseline and each time point. Changes from baseline will be graphically presented. The effect of treatment will be evaluated using a repeated measures model to incorporate assessments across time into a single analysis, using model contrasts to compare treatment groups at selected time points.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Castration Levels of Testosterone</condition>
  <condition>Castration-Resistant Prostate Carcinoma</condition>
  <condition>Metastatic Malignant Neoplasm in the Bone</condition>
  <condition>Prostate Adenocarcinoma</condition>
  <condition>PSA Progression</condition>
  <arm_group>
    <arm_group_label>Arm I (radium Ra 223 dichloride, olaparib)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive radium Ra 223 dichloride IV over 1 minute on day 1. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients also continue to receive olaparib PO BID as in Phase I.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (radium Ra 223 dichloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive radium Ra 223 dichloride as in Arm I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (radium Ra 223 dichloride, olaparib)</arm_group_label>
    <arm_group_label>Arm II (radium Ra 223 dichloride)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (radium Ra 223 dichloride, olaparib)</arm_group_label>
    <other_name>AZD2281</other_name>
    <other_name>KU-0059436</other_name>
    <other_name>Lynparza</other_name>
    <other_name>PARP Inhibitor AZD2281</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radium Ra 223 Dichloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (radium Ra 223 dichloride, olaparib)</arm_group_label>
    <arm_group_label>Arm II (radium Ra 223 dichloride)</arm_group_label>
    <other_name>Alpharadin</other_name>
    <other_name>BAY 88-8223</other_name>
    <other_name>BAY88-8223</other_name>
    <other_name>Radium 223 Dichloride</other_name>
    <other_name>RADIUM RA-223 DICHLORIDE</other_name>
    <other_name>Radium-223 Dichloride</other_name>
    <other_name>Xofigo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have histologically or cytologically confirmed adenocarcinoma of the
             prostate

          -  Participants must have castrate levels of serum testosterone &lt; 50 ng/dL

          -  Participants without orchiectomy must be maintained on luteinizing hormone releasing
             hormone agonist/antagonist; participants receiving prior docetaxel or abiraterone for
             hormone sensitive disease are permitted

          -  Participants must have progressive disease as defined by the following:

               -  Castrate resistant disease as defined by PCWG-3 criteria; participants must have
                  a rise in PSA on two successive determination at least one week apart and PSA
                  levels &gt;= 2 ng/mL (only the screening PS needs to be &gt;= 2 ng/mL) and serum
                  testosterone &lt; 50 ng/dL

               -  Soft tissue progression as defined by RECIST version 1.1

               -  Bone disease progression as defined by PCWG-3 criteria including the development
                  of two or more new lesions on bone scan

          -  Participants must have any number of bone metastases by radiographic imaging

          -  Participants must have tumor accessible for biopsy and be agreeable to baseline tumor
             biopsy

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2 (Karnofsky &gt;= 60%)

          -  White blood cell count (WBC) &gt;= 3,000/mcL

          -  Absolute neutrophil count (ANC) &gt;= 1,500/mcL

          -  Platelets &gt;= 100,000/mcL

          -  Hemoglobin &gt;= 10 g/dL (transfusions permitted)

          -  Total bilirubin =&lt; 1.5 x the institutional upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =&lt; 3 x institutional
             ULN

          -  Creatinine clearance &gt;= 51 ml/min/1.73 m^2 as defined by Cockcroft-Gault equation

          -  Men treated or enrolled on this protocol must agree to use adequate contraception and
             avoid sperm donation prior to the study, for the duration of study participation, and
             three months after discontinuation of olaparib and radium-223 administration

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Pathology consistent with small cell carcinoma of the prostate

          -  Persistent grade &gt; 1 CTCAE version 4.0 adverse events

          -  Presence of visceral metastases (liver, lung, brain, etc.) or malignant
             lymphadenopathy exceeding 4 centimeters (cm) in short diameter

          -  Prior treatment with radium-223; prior treatment with olaparib or other PARP inhibitor
             (PARPi) will be allowed

          -  Treatment with cytotoxic chemotherapy, hormonal therapies (including but not limited
             to abiraterone, enzalutamide), investigational prostate cancer directed therapy within
             4 weeks of treatment initiation

          -  Prior hemibody external radiotherapy

          -  Palliative radiation therapy to the bone or other sites within 2 weeks of treatment
             initiation

          -  Participants who are receiving any other investigational agents

          -  Imminent or established spinal cord compression based on clinical and/or imaging
             findings

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection requiring need for intravenous anti-microbials, symptomatic congestive heart
             failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
             situations that would limit compliance with study requirements

          -  Clinically significant medical condition defined as:

               -  Cerebral infarction within 6 months of study treatment

               -  Transient ischemic attack within 3 months of study treatment

               -  Myocardial infarction within 6 months of study treatment

               -  Uncontrolled angina within 3 months of study treatment

               -  Congestive heart failure New York Heart Association (NYHA) class 3 or 4, or
                  subjects with history of congestive heart failure NYHA class 3 or 4 in the past,
                  or history of anthracycline or anthracenedione (mitoxantrone) treatment, unless a
                  screening echocardiogram or multi‚Äêgated acquisition scan performed within 3
                  months of the screening visit results in a left ventricular ejection fraction
                  that is &gt;= 45%

               -  History of clinically significant ventricular arrhythmias (e.g., ventricular
                  tachycardia, ventricular fibrillation, torsade de pointes)

               -  Prolonged corrected QT interval by the Fridericia correction formula on the
                  screening electrocardiogram (ECG) &gt; 470 msec

               -  History of Mobitz II second degree or third degree heart block without a
                  permanent pacemaker in place

               -  Uncontrolled hypertension as indicated by a resting systolic blood pressure &gt; 170
                  mmHg or diastolic blood pressure &gt; 105 mmHg at the screening visit

               -  History of hypertensive emergency or encephalopathy within 6 months of study
                  treatment

               -  Deep venous thrombosis or pulmonary embolism within 3 months of study treatment

          -  Major surgery within 4 weeks of study treatment; subjects with clinically relevant
             ongoing complications from prior surgery are not eligible

          -  History of gastrointestinal disorders (medical disorders or extensive surgery) which
             may interfere with the absorption of the study drug

          -  History of bowel obstruction within 1 month of study treatment

          -  History of abdominal fistula, intra-abdominal abscess, or gastrointestinal perforation
             within the 3 months of study treatment

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to olaparib

          -  Participants receiving strong or moderate CYP3A4/5 inducers or inhibitors are
             ineligible; dihydropyridine calcium-channel blockers are permitted for management of
             hypertension

          -  Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
             therapy are ineligible

          -  Individuals with a history of a different malignancy are ineligible except for the
             following circumstances:

               -  Individuals with a history of other malignancies are eligible if they have been
                  disease-free for at least 3 years and are deemed by the investigator to be at low
                  risk for recurrence of that malignancy, or

               -  Individuals with the following cancers are eligible if diagnosed and treated
                  within the past 5 years: superficial bladder cancer, basal cell or squamous cell
                  carcinoma of the skin
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rana McKay</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University Cancer Center LAO</affiliation>
  </overall_official>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2017</study_first_submitted>
  <study_first_submitted_qc>October 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Radium Ra 223 dichloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

